- Email: [email protected]
Correction to Lancet Oncol 2015; 16: 545
Corrections
Correction to Lancet Oncol Correction to Lancet Oncol Correction to Lancet Oncol 2013; 14: e374 2015; 16: e163 2015; 16: 447, 448 Weller M, Pfister SM, Wick W, Hegi ME, Reifenberger G, Stupp R. Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncol 2013; 14: e370–79—In the first sentence of the EGFRvIII rearrangement section of this Review, the range of primary glioblastomas with an EGFRvIII deletion should read “20–25%”. This correction has been made as of April 30, 2015.
Correction to Lancet Oncol 2015; 16: 545
Gruber K. Mutation patterns in lung cancer never-smokers. Lancet Oncol 2015; 16: e163—In this News item, the title should have been: “Mutation patterns in lung cancer neversmokers”. The first sentence should read: “Exposure to passive smoke among never smokers does not seem to increase the chances of acquiring somatic mutations in genes linked to non-small-cell lung cancer in smokers, a new study shows.” These corrections have been made as of March 24, 2015.
Krug LM, Kindler HL, Calvert H, et al. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebocontrolled trial. Lancet Oncol 2015; 16: 447–56—In the affiliation section, P Bass should be listed at Netherlands Cancer Institute. In the Funding section in the Summary and in the affiliations, “Merck & Co” has been changed to “Merck & Co, Inc.” These corrections have been made to the online version as of April 30, 2015.
Published Online March 25, 2015 http://dx.doi.org/10.1016/ S1470-2045(14)71115-5
Roschewski M, Dunleavy K, Pittaluga S, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol 2015; 16: 541–49—In the key of figure 2 of this Article, the boxes should indicate patients who were CT positive for disease, not those who were “circulating tumour DNA positive for disease”. This correction has been made to the online version as of April 30, 2015, and the printed version is correct.
www.thelancet.com/oncology Vol 16 May 2015
e199
Correction to Lancet Oncol Correction to Lancet Oncol Correction to Lancet Oncol 2013; 14: e374 2015; 16: e163 2015; 16: 447, 448 Weller M, Pfister SM, Wick W, Hegi ME, Reifenberger G, Stupp R. Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncol 2013; 14: e370–79—In the first sentence of the EGFRvIII rearrangement section of this Review, the range of primary glioblastomas with an EGFRvIII deletion should read “20–25%”. This correction has been made as of April 30, 2015.
Correction to Lancet Oncol 2015; 16: 545
Gruber K. Mutation patterns in lung cancer never-smokers. Lancet Oncol 2015; 16: e163—In this News item, the title should have been: “Mutation patterns in lung cancer neversmokers”. The first sentence should read: “Exposure to passive smoke among never smokers does not seem to increase the chances of acquiring somatic mutations in genes linked to non-small-cell lung cancer in smokers, a new study shows.” These corrections have been made as of March 24, 2015.
Krug LM, Kindler HL, Calvert H, et al. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebocontrolled trial. Lancet Oncol 2015; 16: 447–56—In the affiliation section, P Bass should be listed at Netherlands Cancer Institute. In the Funding section in the Summary and in the affiliations, “Merck & Co” has been changed to “Merck & Co, Inc.” These corrections have been made to the online version as of April 30, 2015.
Published Online March 25, 2015 http://dx.doi.org/10.1016/ S1470-2045(14)71115-5
Roschewski M, Dunleavy K, Pittaluga S, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol 2015; 16: 541–49—In the key of figure 2 of this Article, the boxes should indicate patients who were CT positive for disease, not those who were “circulating tumour DNA positive for disease”. This correction has been made to the online version as of April 30, 2015, and the printed version is correct.
www.thelancet.com/oncology Vol 16 May 2015
e199